The compounds that emerge aren't just theoretical curiosities. They're synthesised and tested, and one targeting fibrosis ...

According to publicly available information from the National Intellectual Property Administration, the patent application date is July 2025, and the publication number is CN120597879A. The core of ...

The last time I wrote about Recursion Pharmaceuticals (NASDAQ:RXRX), it was with respect to a Seeking Alpha article entitled "Recursion: CDK7 Differentiation Is Initially Paying Off." With respect to ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Beijing Zhongke Journal Publising Co. Ltd. The lead author Cheng-Zhi Qin, a professor of geographical information science (GIS) at Institute of Geographic Sciences and Natural Resources Research, ...

Linear type systems permit programmers to deallocate or explicitly recycle memory, but they are severly restricted by the fact that they admit no aliasing. This paper describes a pseudo-linear type ...

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...

AI drug discovery specialist Recursion Pharmaceuticals is shelving three of its most advanced drug prospects in an effort to cut costs following a merger last year. Alongside its latest quarterly ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...